European Stroke Organizational Report

During the past 3 years, the European Stroke Organisation (ESO) has seen the launch of its annual congress, its growing attendance, and a boom in the society’s membership with currently u003e7000 professionals enrolled as members. Within this 3-year period, 36 National Stroke societies throughout the world have joined as associate members with the expressed intent to adhere to and promote stroke diagnosis and treatment according to ESO stroke treatment standards.At the 2017 ESO Conference (ESOC) held in Prague, and chaired by Martin Dichgans, the number of submitted abstracts was u003e1800, and the number of participants exceeded 4000 clinicians, researchers, and other healthcare professionals. Many investigators chose ESOC 2017 to present landmark results of their studies, including u003e12 randomized controlled trials. Tudor Jovin and Raul G. Nogueira presented the final results from the DAWN trial (Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention With Trevo) reporting superior functional outcomes at 90 days with endovascular thrombectomy plus medical management compared with medical management alone in carefully selected patients with ischemic stroke and a proximal intracranial artery occlusion, treated 6 to 24 hours after last seen. Two trials on patent foramen ovale closure were presented: CLOSE (Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence) and Gore-REDUCE (GORE® HELEX® Septal Occluder / GORE® Septal …